Enliven Therapeutics Inc (NASDAQ: ELVN) is 82.80% higher on its value in year-to-date trading and has touched a low of $9.80 and a high of $27.67 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ELVN stock was last observed hovering at around $26.00 in the last trading session, with the day’s loss setting it -0.7%.
Currently trading at $25.30, the stock is 9.38% and 8.96% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.13 million and changing -2.69% at the moment leaves the stock 29.21% off its SMA200. ELVN registered 84.94% gain for a year compared to 6-month gain of 36.09%. The firm has a 50-day simple moving average (SMA 50) of $23.2342 and a 200-day simple moving average (SMA200) of $19.647276.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 13.96% loss in the last 1 month and extending the period to 3 months gives it a 17.40%, and is 4.42% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.70% over the week and 5.40% over the month.
Enliven Therapeutics Inc (ELVN) has around 46 employees, a market worth around $1.20B and $0.00M in sales. Distance from 52-week low is 158.16% and -8.58% from its 52-week high. The company has generated returns on investments over the last 12 months (-27.16%).
Enliven Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -0.5.The EPS is expected to grow by 3.31% this year
145.0 institutions hold shares in Enliven Therapeutics Inc (ELVN), with institutional investors hold 110.11% of the company’s shares. The shares outstanding are 41.29M, and float is at 28.89M with Short Float at 19.15%. Institutions hold 102.83% of the Float.
Enliven Therapeutics Inc (ELVN) Insider Activity
The most recent transaction is an insider sale by Hohl Benjamin, the company’s CHIEF FINANCIAL OFFICER. SEC filings show that Hohl Benjamin sold 4,250 shares of the company’s common stock on Sep 27 ’24 at a price of $24.27 per share for a total of $0.1 million. Following the sale, the insider now owns 0.0 shares.
Enliven Therapeutics Inc disclosed in a document filed with the SEC on Sep 30 ’24 that Hohl Benjamin (CHIEF FINANCIAL OFFICER) sold a total of 2,000 shares of the company’s common stock. The trade occurred on Sep 30 ’24 and was made at $25.33 per share for $50668.0. Following the transaction, the insider now directly holds 0.0 shares of the ELVN stock.
Still, SEC filings show that on Oct 01 ’24, Hohl Benjamin (Officer) Proposed Sale 12,009 shares at an average price of $25.54 for $0.31 million. The insider now directly holds shares of Enliven Therapeutics Inc (ELVN).
